Capitalization 15.96M P/E ratio 2022
-3.29x
P/E ratio 2023 -0.26x
Enterprise value 37.74M EV / Sales 2022
1.8x
EV / Sales 2023 71.2x
Free-Float
70.09%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.14%
1 week-3.14%
Current month+13.00%
1 month+11.15%
3 months+33.68%
6 months+111.88%
Current year+35.41%
More quotes
1 week
0.64
Extreme 0.64
0.80
1 month
0.54
Extreme 0.54
0.85
Current year
0.25
Extreme 0.25
0.91
1 year
0.25
Extreme 0.25
1.17
3 years
0.25
Extreme 0.25
5.49
5 years
0.25
Extreme 0.25
8.30
10 years
0.25
Extreme 0.25
16.80
More quotes
Manager TitleAgeSince
Founder 70 08-06-04
Chief Executive Officer 55 12-02-01
Director of Finance/CFO 54 Jan. 01
Director TitleAgeSince
Chief Executive Officer 55 12-02-01
Director/Board Member 53 12-04-16
Director/Board Member 58 17-02-21
More insiders

Other Medical Equipment, Supplies & Distribution

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-3.14%-3.14%-37.80%-87.18% 32.01M
+1.66%+0.74%-9.25%-12.29% 180B
-0.23%+2.88%-10.86%-37.61% 102B
+0.15%+2.22%-12.74%-7.32% 66.79B
-0.01%-1.20%-14.51%-0.95% 44.4B
-1.91%-9.14%+16.51%+22.29% 41.92B
+0.50%+1.13%+16.68%+87.52% 44.25B
+2.11%+1.04%+0.79%-5.96% 29.32B
-2.00%-1.23%+22.36%+28.36% 26.29B
+0.03%-0.65%-15.72%-14.96% 23.17B
Average -0.28%-0.32%-4.45%-2.81% 55.83B
Weighted average by Cap. +0.43%+0.53%-4.64%-2.77%
See all sector performances
Ratios2022 2023
Net sales 36.02M 530K
Net income -14.89M -55.36M
Net Debt 14.96M 21.78M
More financial data * Estimated data
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
146
More about the company
Date Price Change Volume
24-07-23 0.6858 $ +1.15% 478
24-07-22 0.6780 $ -3.14% 88,183
24-07-19 0.7000 $ 0.00% 11,443
24-07-18 0.7000 $ -2.49% 45,732
24-07-17 0.7179 $ +2.54% 30,252

Delayed Quote Nasdaq, July 22, 2024 at 04:00 pm EDT

More quotes